Floatz logo

Anti Cd30 Car-T Cell

Peripheral T Cell Lymphoma, Unspecified

Zhejiang UniversityCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

135 Active assets in the Peripheral T Cell Lymphoma, Unspecified cohort.

Asset / SponsorPhaseRating
Inno-206
BeBetter Med Inc
Phase 4BBB
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
Pralatrexate
Peking University People's Hospital
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB

View all 50 →

Same molecule, other indications

Anti Cd30 Car-T Cell is also rated in:

extranodal nasal NK/T cell lymphomaDormant
C
Indicative ·
39 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
C
Indicative ·
39 / 100
View asset →
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →